March 11, 2019 / 8:40 PM / 2 months ago

FDA approves Pfizer's biosimilar to Roche's Herceptin

March 11 (Reuters) - The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster treatment for breast cancer, Herceptin.

The approval comes nearly a year after the agency declined to approve the drug, Trazimera, asking for additional technical information. (Reporting by Tamara Mathias in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below